India's Central Drugs Standard Control Organization has released its proposed clinical trial reforms, and while most fall in line with industry expectations, ACRO says the suggested rules on patient compensation are vague and problematic.
Pfizer is dumping its clinical research operation in Singapore, part of an effort to cut about $1.3 billion from its R&D budget, and the divestiture could mean more opportunity for outsourcers looking to partner with the drug giant.
With Western drugmakers sniffing around emerging markets in Latin America and elsewhere for the scent of a good deal, some companies there are weighing their futures, and their values, preparing themselves for the chase.
As Pfizer continues to cut costs, it has just taken the ax to a clinical research facility in a market where others are beefing up, Singapore.
Switzerland's Biosensors International will work with Japan's Terumo to promote that company's Nobori drug-eluting stent in Japan.
China has stepped up efforts to battle the counterfeits and the weak links in its API and drug supply industries that have tainted its reputation. It has raided unlicensed plants and made arrests, and now it has sent some of those involved to jail.
Two consumer health deals, two Big Pharma approaches toward emerging markets. While Bristol-Myers Squibb is looking around for buyers for a portfolio of consumer brands in Latin America, GlaxoSmithKline has staked another $900 million on the consumer health market in India.
An engineer in India has come up with an inexpensive needle free blood diagnostic that can help cheaply diagnose anemia, the Mumbai Mirror reports.
As India's government churns over the idea of tightening clinical trial regulations, a private industry group is entering the fold and launching a committee designed to improve transparency.
Cargo theft of pharmaceuticals in Mexico is becoming more frequent and more costly.